SGSusan Guy

Susan Guy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan Guy has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A review of the monitoring of argatroban by anti-IIa methods, ecarin assays, point-of-care testing methods and specialized drug quantification methods for patients with heparin-induced thrombocytopenia

    by Susan Guy, Kevin Horner, Kerensa Leeson, Rhona Maclean

    Heparin-induced thrombocytopenia (HIT) is caused by anti-PF4/heparin IgG antibodies stimulating platelet activation, causing thrombocytopenia and thrombosis. Classical HIT occurs due to exposure to heparin, whereas autoimmune HIT occurs via heparin-independent platelet activation (caused by anti-PF4/polyanion IgG) and relates to a platelet count fall that begins or persists without heparin. Treatment for HIT requires transitioning patients onto alternative anticoagulation. The direct thrombin inhibitor argatroban has been licensed for use in patients with HIT and was recommended to be monitored by the activated partial thromboplastin time (aPTT). Recent European guidelines have suggested that monitoring drug concentrations is more suitable and will reduce the risk of under or over anticoagulating patients. This review will discuss anti-IIa and ecarin-based laboratory methods for determining plasma argatroban concentrations, the use of viscoelastography methods and other point-of-care testing (POCT) methods in whole blood. The use of more specialised tests based on high-performance liquid chromatography will also be discussed, comparing these methods with aPTT.

  • Review of the Current Issues Surrounding Monitoring of the Direct Thrombin Inhibitor Argatroban in the Laboratory

    by Susan Guy, Kieron Hickey, Rhona Maclean

    The direct thrombin inhibitor argatroban is licensed for use in Heparin‐induced thrombocytopenia. Original trial data gave the recommendation of monitoring argatroban by Activated Partial Thromboplastin Time (APTT) stating a therapeutic target range of 1.5–3.0 times baseline APTT and not exceeding 100 s. APTT has limitations due to prolongation arising in factor deficiencies, lupus anticoagulants, liver disease, and high FVIII levels leading to potential overestimation of argatroban. Argatroban has demonstrated a plateau effect on APTT at higher concentrations; additionally, APTT reagents have different sensitivity to argatroban, potentially underestimating or overestimating the argatroban. Anti‐IIa methods have been recommended as a suitable alternative to accurately quantify argatroban levels. However, there is a lack of consensus on what the target therapeutic range should be. This review will demonstrate how argatroban monitoring by APTT may not be the most suitable method to successfully dose argatroban based on the current state of knowledge and recent published guidelines and highlight the benefits of the anti‐IIa methods.


  • Evaluation of one‐stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion

    by Sean Platton, Priyanka Raheja, Christopher Dale, Susan Guy, Nada Yartey, Annette Bowyer


  • Agreement between one stage and chromogenic assays in samples from patients receiving recombinant porcine FVIII (Obizur, Susoctocog‐alfa)

    by Susan Guy, Annette E. Bowyer, M. Fiona Shepherd, Rhona M. Maclean, Steve Kitchen

    Introduction: Recombinant porcine FVIII (rpFVIII) (Obizur, Susoctcog‐alfa, Takeda, Japan) is licensed for the treatment of bleeding in acquired Haemophilia A (AHA). The summary of product characteristics state that monitoring should be by one stage assay (OSA) rather than chromogenic assay (CSA). CSA have been shown to underestimate activity when rpFVIII is added to plasma in vitro.Methods: Samples from three AHA patients (n = 21) (pre‐ and post rpFVIII) were assessed using FVIII:C assays; OSA methods: Actin, Actin FS, Actin FSL and Pathromtin SL performed on CS5100i (Sysmex, Kobe, Japan); APTT‐SP, SynthASil and SynthAFax performed on ACL TOP (Werfen, Barcelona, Spain). CSA methods on CS5100i: Siemens Chromogenic Assay, Biophen FVIII:C, Technochrom FVIII:C; on ACL TOP: Rox Factor VIII, Coamatic Factor VIII and CRYOcheck Factor VIII.Results: OSA and CSA varied according to reagent used median OSA 61 IU/dL (range 41.5–81 IU/dL (ANOVA p < 0.0001)) median CSA 46.5 IU/dL (range of method specific medians 36.5–84 IU/dL (ANOVA p < 0.0001)). Amongst OSA, Actin FS was associated with the highest FVIII:C, APTT‐SP was associated with the lowest. Variation in CSA results by different methods was also seen with highest FVIII:C levels obtained using the Technochrom FVIII:C and the lowest levels obtained with Siemens Assay.Conclusion: The relationship between OSA and CSA was not consistent between method or patient. Previously there has been reports of underestimation by CSA in in vitro spiked samples. Investigation into concentration of phospholipids in the APTT reagents may explain some of these variations.


  • How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?

    by Susan Guy, M. Fiona Shepherd, Annette E. Bowyer, Steve Kitchen

    Introduction: Non‐parallelism in factor assays can lead to incorrect factor activities. Parallelism can be assessed by calculating the coefficient of variation (CV) of results obtained on 3 dilutions of the same sample. Some authors have proposed that if there is 25 IU/dl (plus no interfering substances) all CVs were < 15%. One sample (low factor activities 10–15 IU/dl), had CVs > 15% in FII, FVII and FXII assays only. SR outside of 0.9–1.1 were seen in FII and FXII assays at different levels of clotting factor including some within the normal range. Non‐parallelism was detected more frequently with SR than CV for those with interfering substances.Conclusions: SR outside of 0.9–1.1 were seen in different levels of clotting factors, including samples which did not contain interfering substances. The target of 15% CV was a better discriminator than a SR for acceptance. When factor levels were reduced to around 10–15 IU/dl, a target 20 %CV was more appropriate than 15%. It might be appropriate for laboratories to assess locally whether their acceptance criteria need to be wider at low levels of clotting factors.


  • Laboratory methods for monitoring argatroban in heparin‐induced thrombocytopenia

    by Susan Guy, Steve Kitchen, Barbara Hopkins, Zunaid Chunara, Alex Stephenson‐Brown, Joost J. van Veen

    Introduction: The Summary of Product Characteristics for the direct thrombin inhibitor argatroban states monitoring should be by activated partial thromboplastin time (APTT), with a target range of 1.5‐3.0 times the patients' baseline APTT. APTT may be influenced by coagulopathies, lupus anticoagulant and raised FVIII levels. Previous studies have shown sensitivity differences of APTT reagents to argatroban. Some recent publications have favoured the use of anti‐IIa methods to determine the plasma drug concentration of argatroban. This study aims to compare the anti‐IIa assays: Hemoclot thrombin inhibitor assay (HTI) and Ecarin chromogenic assay (ECA) alongside the APTT.Methods: Residual plasma of 25 samples from 8 patients (3 with COVID‐19 and HIT: n = 18, 5 with HIT: n = 7) was tested at two sites: site A: Sysmex CS5100 by HTI and APTT (Actin FS and SynthASil), and also on Stago STA Compact Max: ECA and APTT (CK Prest); and site B: Stago STA R Max 2 by ECA and APTT (Cephascreen).Results: Mean APTT ratio was 1.96 (Actin FS), 1.84 (SynthASil), 1.59 (CK Prest) and 2.48 (Cephascreen). Mean argatroban concentration by HTI was 0.60 µg/mL and by ECA was 0.65 µg/mL (site A) and 0.70 µg/mL (site B). There was a poor correlation to HTI in APTT ratios (range r2 = .0235‐0.4181) with stronger correlations between ECA methods to HTI (r2 = .8998 site A, r2 = .8734 site B).Conclusion: This study confirms previous publications on the unsuitability of APTT and expands this by being multisited and included APTT reagents that use mechanical clot detection. Both anti‐IIa methods are more suitable.


  • Open Access

    Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)

    by Susan Guy, Steve Kitchen, Michael Makris, Rhona M. Maclean, Giorgia Saccullo, Joost J Vanveen

    Introduction: Argatroban is licensed for patients with heparin-induced thrombocytopenia and is conventionally monitored by activated partial thromboplastin time (APTT) ratio. The target range is 1.5 to 3.0 times the patients’ baseline APTT and not exceeding 100 s, however this baseline is not always known. APTT is known to plateau at higher levels of argatroban, and is influenced by coagulopathies, lupus anticoagulant and raised FVIII levels. It has been used as a treatment for COVID-19 and Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). Some recent publications have favored the use of anti-IIa methods to determine the plasma drug concentration of argatroban. Methods: Plasma of 60 samples from 3 COVID-19 patients and 54 samples from 5 VITT patients were tested by APTT ratio and anti-IIa method (dilute thrombin time dTT). Actin FS APTT ratios were derived from the baseline APTT of the patient and the mean normal APTT. Results: Mean APTT ratio derived from baseline was 1.71 (COVID-19), 1.33 (VITT) compared to APTT ratio by mean normal 1.65 (COVID-19), 1.48 (VITT). dTT mean concentration was 0.64 µg/ml (COVID-19) 0.53 µg/ml (VITT) with poor correlations to COVID-19 baseline APTT ratio r2 = 0.1526 p 2 = 0.2188 p < 0.0001; VITT baseline APTT ratio r2 = 0.04 p < 0.001, VITT mean normal r2 = 0.0064 p < 0.001. Conclusions: We believe that dTT is a superior method to monitor the concentration of argatroban, we have demonstrated significant differences between APTT ratios and dTT levels, which could have clinical impact. This is especially so in COVID-19 and VITT.


  • A cost‐effective approach to factor assay calibration using a truncated live calibration curve

    by Susan Guy, Anne M. Sermon‐Cadd, Fiona M. Shepherd, Steve Kitchen, Annette E. Bowyer

    Introduction: The measurements of clotting factor activities are usually performed using a one‐stage clotting assay (OSA) or chromogenic substrate assay (CSA). Advances in automated coagulation analysers have led to the utilization of stored calibration curves. There are sometimes substantial intervals between test calibration and analysis of samples. Variability in results can be influenced by calibrant and methodology. Several guidelines recommend calibration and patient samples be performed together in parallel; this incurs costs, but reliance on a stored calibration curve may lead to inaccuracy of results over time.Methods: We evaluated inclusion of a live truncated (3 point) calibration curve using calibrator plasma alongside test samples and compared results calculated against the stored calibration curves and live truncated calibration to assess the impact on precision and accuracy. The feasibility of this was tested on two hospital sites in the UK; OSA and CSA were performed on Sysmex CS5100 using Actin FS, SynthASil, Innovin, Biophen chromogenic VIII and Rossix chromogenic IX.Results: Results of two batches of IQC were compared for FII, FV, FVII, FX, FIX:C, FXI, FXII and OSA FVIII (FVIII:C1) and CSA FVIII:C (FVIII:CR) and FXI:C. By utilizing a live truncated calibration, precision improved with the most striking examples: FXII %CV 23.1% to 3.1% (site A) FXI 7.3% to 2.4% (site B). The improvement in other clotting factors was more modest.Conclusion: To the best of our knowledge, this is the first study that demonstrates that the use of a live truncated calibration curve will improve precision and accuracy.


  • Argatroban is stable in citrated whole blood for 24 hours

    by S. Guy, S. Kitchen, J. J. Van Veen

    Introduction: Argatroban is a direct thrombin inhibitor used as an anticoagulant for patients who have Heparin induced thrombocytopenia. Quantification can be performed using a dilute thrombin time or anti‐iia assay. Our preferred method is Hemoclot Thrombin Inhibitor Assay (HTI).To the best of our knowledge, no one has published on the stability of plasma argatroban in whole citrated blood at room temperature.Methods: Forty matched samples obtained from 4 patients receiving argatroban. 1 mL of the whole blood was removed from the sample into a labelled plastic tube and left on the laboratory bench at room temperature for 24 hours prior to centrifugation. The remaining sample was spun at 2000 g for 10 minutes and the plasma aliquoted off and labelled 0 hour and stored at −80°C prior to testing. At 24 hours the plastic tube containing whole blood was centrifuged at 2000 g for 10 minutes and the plasma aliquoted off and labelled 24 hours and stored at −80°C prior to testing. HTI assay was used for plasma argatroban determination.Results: The lowest argatroban level obtained was 0.16 μg/mL at 0 hour; 0.18 μg/mL at 24 hours from the same pair, the highest argatroban level obtained was 1.72 μg/mL at 0 hour;1.76 μg/mL for the same pair at 24 hours. The mean result for 0 hour was 0.57 μg/mL and 0.60 μg/mL at 24 hours.Conclusion: This study proposes that patients receiving treatment in hospitals who cannot provide a dedicated argatroban plasma concentration method could have their samples sent on whole blood within 24 hours of venepuncture to a laboratory who could provide the test.


  • More on the Limitations of the Activated Partial Thromboplastin Time for Monitoring Argatroban Therapy

    by Joost Van Veen, Steve Kitchen, Susan Guy

    We read with interest the recent article on laboratory monitoring of parental direct thrombin inhibitors by Van Cott et al.[1] This is a welcome addition to the literature assisting laboratories in a difficult area. We agree that the activated partial thromboplastin time (aPTT) assay is the most commonly used method for monitoring patients on argatroban. We would like the opportunity to offer additional considerations on the use of aPTT, including its limitations, and the advantages of using the less common methods of drug calibrated specific assays. The cited target range of 1.5 to 3 × baseline aPTT ratio not exceeding 100s, from the Summary of Product Characteristics (SmPC) addressing the use for argatroban, is partly based on an early trial[2] that permitted inclusion of patients with a baseline aPTT ratio of up to 2 (i.e., with gross prolongation of aPTT in advance of any argatroban infusion); thus, some cases might have been within the assigned target range for therapy before any drug was even administered. This could be caused by the underlying condition of the patient with associated coagulopathy. This is an obvious limitation of use of aPTT for monitoring. The authors of the recent article in this journal[1] acknowledge that monitoring of argatroban using aPTT alone is difficult or impossible if the patient has a prolonged aPTT at baseline (e.g., caused by lupus anticoagulants or deficiencies in factors VIII, IX, XI, or XII). There is a good deal of additional literature evidence identifying the potential problems of using the aPTT as the only test to monitor argatroban. Curvers et al[3] suggest that this will lead to overestimation of the drug concentration. Furthermore, as mentioned by Van Cott and coworkers,[1] aPTT has been shown to have some plateau effect with argatroban, and Keyl et al[4] showed that in critically ill patients, this plateau occurred at 72 seconds (determined using Pathromtin SL) and equivalent to a drug concentration of 0.85 µg/mL. In the original trial,[5] aPTT using Actin FSL also showed a plateau effect, which occurred at 1 µg/mL. Underestimation of drug concentration and argatroban “resistance” has also been demonstrated in elevated levels of factor VIII.[6] Plasma in patients with liver disease spiked with argatroban demonstrated that they would receive lower doses of argatroban than those without liver disease, if using the aPTT to monitor.[7] Wanat et al[8] have demonstrated in a patient that the dilute thrombin time (dTT) assay was normal (26.4s), whereas the aPTT remained prolonged (53.9s) after 11 hours of argatroban infusion. Taking these limitations of aPTT into account, we believe that it is to understand the relationship between the aPTT and argatroban concentration in patients (e.g., where aPTT baseline is prolonged) during the early stages of therapy and to monitor some patients by quantifying the plasma argatroban levels. In addition, we have demonstrated that there are different sensitivities to argatroban with different aPTT reagents in samples collected from patients during argatroban therapy[9] and in spiked plasma prepared by addition of drug to plasma in vitro.[10] In our study of patient samples,[9] the reagent least sensitive to argatroban (among six reagents studied) was Actin FSL (with a mean ratio of 1.6 in 57 patient samples) with the most sensitive being SynFAx (with mean aPTT ratio of 2.3). The correlation between aPTT ratio and argatroban concentration was poor for all six reagents (r = 0.07–0.29), and we have demonstrated that the correlation between argatroban and aPTT is different from analyses of ex vivo samples versus in vitro spiking.[10] In 57 patient samples[9] with a mean argatroban concentration of 0.43 µg/mL, the mean aPTT ratio using Actin FSL was 1.58, whereas in spiked samples an aPTT ratio of 1.5 with the same reagent corresponded to a much higher argatroban concentration of 0.84 µg/mL; accordingly, we strongly agree with Van Cott et al[1] that the use of assay calibrators and spiked plasmas should not be recommended for assessing target ranges for a particular aPTT method. We would also like to use this opportunity to share new data. In previous work, we have demonstrated a discrepancy in aPTT ratio with different reagents. Also, with one of our argatroban administered patients, argatroban levels were determined using Hemoclot thrombin inhibitor (HTI) Assay (Hyphen Biomed Neuville-sur-Oise, France). Prior to argatroban administration we measured and saw a difference in their baseline aPTT ratios using Actin FS (ratio 1.9) and SynthASil (ratio: 1.1). During argatroban therapy the patient had a mean argatroban level of 1.04 µg/mL (range: 0.5–1.76 µg/mL), corresponding to different aPTT ratios with different reagents (Actin FS, mean (range) ratio of 3.1 (2.1–4.1); SynthAsil, mean (range) ratio of 1.6 (1.1–2.1)). Thus, some of these results would have suggested the patient was over-anticoagulated (if the Actin FS was used for monitoring, thereby indicating the dose should be reduced), whereas no action would be taken if using SynthAsil. In our previous data,[9] we demonstrated that SynthAsil and Actin FSL had similar low aPTT ratios with patients on argatroban, whereas Actin FS gave higher aPTT ratios in patient samples. Actin FSL was used in the initial trial of healthy patients, which gave rise to the aPTT ratio range of 1.5 to 3 times baseline aPTT.[5] One important problem with the use of argatroban assays for monitoring is the lack of studies in which a therapeutic range has been established using clinical outcomes. This means there is no consensus on what the argatroban therapeutic range concentration should be. For example, Love et al[11] cite a therapeutic range by dilute thrombin time as being nearly 55 to 98 seconds, based on spiked samples of 0.2 to 2.2 µg/mL. The upper value is higher than any other observed value we found in our literature review.[10] Van Cott et al[1] describe a tentative proposed range of 0.6 to 1.8 µg/mL. The lower level of 0.6 µg/mL is higher than any we have seen in the literature. The most recently cited range extrapolated that utilizing the HTI gave rise to a range of 0.25 to 1.5 µg/mL.[12] A recent publication has considered clinical outcomes and also compared the aPTT to chromogenic anti-IIa assay and cites a range of 0.4 to 1.2 µg/mL for that particular assay.[13] The authors described new thrombosis cases with prolonged baseline aPTT and concluded that monitoring should use anti-IIa activity rather than aPTT. In our experience, HTI is a very robust assay and produces very reproducible results (in house reproducibility demonstrated CVs of 2.9–4.6%). Linearity of the calibration curve is 0 to 1.95 µg/mL (r 2 = 0.999), with a lower limit of quantification (LLQ) determined as 0.03 µg/mL (we recommend checking the [LLQ] for each new lot of reagent). We agree that there is no agreed therapeutic range for argatroban by drug concentration, but this is not sufficient reason to rely solely on the aPTT. It is also of concern that some recommendations utilize 100 seconds as a cutoff because we have demonstrated,[9] as have others,[11] that this may sometimes lie within the therapeutic range of 1.5 to 3 by aPTT ratio. More data are needed to link argatroban concentrations to clinical outcomes during therapy for heparin-induced thrombocytopenia (HIT). In the meantime, aPTT results during argatroban therapy should be interpreted with caution, and determination of argatroban concentration by a calibrated quantitative assay can give useful additional information.